Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus + exemestane versus ridaforolimus + dalotuzumab + exemestane in ER-positive high-proliferation breast cancer
2012-000335-11Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Ridaforolimus + exemestane with Ridaforolimus + dalotuzumab + exemestane (2 arms). Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
ridaforolimusdalotuzumabexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000335-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000335-11.